Hackam Daniel G
Division of Clinical Pharmacology & Toxicology, Sunnybrook & Women's College Health Sciences Center, Toronto, Ontario, Canada.
J Vasc Surg. 2006 Mar;43(3):632-4. doi: 10.1016/j.jvs.2005.12.014.
Patients undergoing vascular surgery comprise a group at elevated risk of fatal and nonfatal perioperative cardiovascular events. In four recent longitudinal studies, the 30-day incidence of death in such patients was 3% to 6%, and the incidence of myocardial infarction was 5% to 14%. Growing evidence suggests that beta-adrenergic receptor antagonists prevent cardiovascular morbidity and mortality in high-risk patients undergoing noncardiac surgery, including those undergoing vascular surgery. This article reviews the available evidence concerning beta-blockers and provides guidance for their use in the perioperative setting.
接受血管手术的患者是围手术期发生致命和非致命心血管事件风险较高的群体。在最近的四项纵向研究中，这类患者30天的死亡率为3%至6%，心肌梗死发生率为5%至14%。越来越多的证据表明，β-肾上腺素能受体拮抗剂可预防接受非心脏手术的高危患者（包括接受血管手术的患者）发生心血管疾病并降低死亡率。本文回顾了有关β受体阻滞剂的现有证据，并为其在围手术期的使用提供指导。
